We are thrilled to announce that Altratech Limited has successfully raised $10,500,000 in our latest funding round, marking a significant milestone in our mission to revolutionize molecular detection. Our dedicated team of scientists and engineers, specializing in molecular biology, surface chemistry, microfluidics, and chip design, has been working tirelessly to integrate nano biotechnology, chemistry, and semiconductors to transform the landscape of genetic data accessibility. With this substantial investment, we are poised to further our vision of creating a robust technological infrastructure for managing contagious viral diseases, which is crucial for the future of decentralized connected healthcare and overall wellbeing.
The funding will play a pivotal role in advancing our groundbreaking Detection by Proxy concept, enabling rapid and accurate measurement of viral RNA, DNA, antigen, or antibody samples in a user-friendly manner. By shifting the monitoring of viral contagious diseases to point-of-care and home settings, we aim to dismantle common barriers associated with sample preparation, reagent storage, and expertise requirements. Our innovative KeyChain PNA probe, along with our novel detection methodologies, will empower individuals to monitor their health 'anywhere, anytime, by anyone'. With this funding, Altratech is set to lead the charge in making molecular diagnostics more accessible and practical, paving the way for proactive health management and improved outcomes in infectious disease control. Stay tuned as we continue to innovate and expand our capabilities in empowering individuals to take charge of their health through cutting-edge technology.
